MX2017009452A - Agentes de imagenologia para tomografia de emision de positrones (pet). - Google Patents

Agentes de imagenologia para tomografia de emision de positrones (pet).

Info

Publication number
MX2017009452A
MX2017009452A MX2017009452A MX2017009452A MX2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A MX 2017009452 A MX2017009452 A MX 2017009452A
Authority
MX
Mexico
Prior art keywords
imaging agents
pet imaging
formula
preparation
novel
Prior art date
Application number
MX2017009452A
Other languages
English (en)
Spanish (es)
Inventor
Oberhauser Berndt
Briard Emmanuelle
Auberson Yves
Legrand Darren
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2017009452A publication Critical patent/MX2017009452A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus or devices for radiation diagnosis; Apparatus or devices for radiation diagnosis combined with radiation therapy equipment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medical Informatics (AREA)
  • Engineering & Computer Science (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nuclear Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2017009452A 2015-01-20 2016-01-20 Agentes de imagenologia para tomografia de emision de positrones (pet). MX2017009452A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105336P 2015-01-20 2015-01-20
PCT/IB2016/050276 WO2016116875A1 (en) 2015-01-20 2016-01-20 Pet imaging agents

Publications (1)

Publication Number Publication Date
MX2017009452A true MX2017009452A (es) 2017-11-08

Family

ID=55300733

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009452A MX2017009452A (es) 2015-01-20 2016-01-20 Agentes de imagenologia para tomografia de emision de positrones (pet).

Country Status (12)

Country Link
US (2) US10450298B2 (cg-RX-API-DMAC10.html)
EP (1) EP3247706B1 (cg-RX-API-DMAC10.html)
JP (2) JP6723264B2 (cg-RX-API-DMAC10.html)
KR (1) KR20170103960A (cg-RX-API-DMAC10.html)
CN (1) CN107406419B (cg-RX-API-DMAC10.html)
AU (1) AU2016209906A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017015455A2 (cg-RX-API-DMAC10.html)
CA (1) CA2974311A1 (cg-RX-API-DMAC10.html)
EA (1) EA201791643A1 (cg-RX-API-DMAC10.html)
ES (1) ES2828715T3 (cg-RX-API-DMAC10.html)
MX (1) MX2017009452A (cg-RX-API-DMAC10.html)
WO (1) WO2016116875A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170103960A (ko) 2015-01-20 2017-09-13 노파르티스 아게 Pet 영상화제
TWI809597B (zh) * 2020-12-16 2023-07-21 美商美國禮來大藥廠 預靶向造影劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
WO2005043300A2 (en) 2003-10-20 2005-05-12 Empirix, Inc. Computer language interpretation and optimization for server testing
EP1740565A2 (en) 2004-04-28 2007-01-10 ICOS Corporation Arylphenylamino-, arylphenylamide-, and arylphenylether-sufide derivatives
WO2005121094A1 (en) 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
CN101429161A (zh) * 2008-12-05 2009-05-13 常熟理工学院 Pet显像剂前体异喹啉甲酰胺衍生物的合成方法
JP5767205B2 (ja) * 2009-04-02 2015-08-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung オートタキシン阻害剤としての複素環式化合物
WO2012020567A1 (en) 2010-08-09 2012-02-16 Raqualia Pharma Inc. Acyl piperazine derivatives as ttx-s blockers
EP2606031B1 (en) * 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
SI2861566T1 (sl) * 2012-06-13 2017-03-31 F. Hoffmann-La Roche Ag Novi diazaspirocikloalkan in azaspirocikloalkan
EP2935249B1 (en) 2012-12-19 2018-12-12 Novartis AG Autotaxin inhibitors
PT3022202T (pt) * 2013-07-18 2019-09-03 Novartis Ag Inibidores da autotaxina compreendendo um núcleo beteroaromático anel-benzilo-amida-ciclo
KR20170103960A (ko) 2015-01-20 2017-09-13 노파르티스 아게 Pet 영상화제

Also Published As

Publication number Publication date
US10450298B2 (en) 2019-10-22
CN107406419B (zh) 2020-09-11
BR112017015455A2 (pt) 2018-01-23
JP2018511648A (ja) 2018-04-26
EP3247706B1 (en) 2020-07-08
US20200017474A1 (en) 2020-01-16
WO2016116875A1 (en) 2016-07-28
CN107406419A (zh) 2017-11-28
JP2020158532A (ja) 2020-10-01
CA2974311A1 (en) 2016-07-28
AU2016209906A1 (en) 2017-08-03
KR20170103960A (ko) 2017-09-13
JP6723264B2 (ja) 2020-07-15
US20180273509A1 (en) 2018-09-27
US10865195B2 (en) 2020-12-15
EP3247706A1 (en) 2017-11-29
ES2828715T3 (es) 2021-05-27
EA201791643A1 (ru) 2017-11-30
CN107406419A8 (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
PH12016501898A1 (en) Quinoxaline derivatives useful as fgfr kinase modulators
PH12015502216A1 (en) Compositions and methods for improving the health of aquatic animals
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX385332B (es) Moduladores de ror-gamma.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
NZ758528A (en) Bicyclic heterocycle compounds and their uses in therapy
MX381383B (es) Compuestos de 6,8-dioxabiciclo[3.2.1]octano-2,3-diol sustituidos como agentes de direccionamiento al receptor de asialoglicoproteina (asgpr)
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
EA201691141A1 (ru) Соединения против ccr6
EA201691541A1 (ru) Новые анти-baff антитела
MX388170B (es) Polimorfos de selinexor
EP3760625C0 (en) BICYCLIC LACTAMS AS PROTEIN KINASE 1 (RIP1) INHIBITORS INTERACTING WITH RECEPTORS FOR TREATMENT E.G. OF INFLAMMATORY DISEASES
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MY193728A (en) Muscarinic receptor agonists
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
EA201890572A1 (ru) Биофармацевтические композиции
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017003254A (es) 2-azabiciclos sustituidos y su uso como moduladores de receptores de orexina.
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
WO2016138538A3 (en) Therapeutic use of integrin-binding antibodies